Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition - Pharmafile

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition - Pharmafile

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment of IgG4-related disease (IgG4-RD), a chronic inflammatory condition. The designation is given to therapies targeting rare, serious or debilitating conditions affecting no more than five in 10,000 people in the EU. The decision follows positive […] The post Sanofi’s treatment granted o…